8 days ago
Pfizer (NYSE: PFE) is offering a dividend yield of roughly 6% today. That is well above the roughly 1% yield on offer from the S&P 500 index (SNPINDEX: ^GSPC) and the 1.4% average yield of pharmaceutical stocks. There are good reasons for the negative view of Pfizer, but investors may be ignoring the company's over 100-year history of success. Here's why you may want to consider buying this out-of-favor dividend stock while others are fearful.
Pfizer's stock rocketed higher during the coronavirus pandemic, as investors myopically focused on the company's COVID vaccine. When COVID turned out to be a less serious long-term threat than originally believed, Wall Street dumped Pfizer. At this point, the stock is down more than 50% from its 2021 high. That is a big part of the story behind the high yield.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
However, there's another piece that is more fundamental to the pharmaceutical industry. Like all drug makers, Pfizer's drugs receive time-limited patent protections. When patents expire, generic versions of the medications can be produced. That generally leads to a dramatic decline in revenue from Pfizer's drugs. Right now, Pfizer is facing down some notable patent expirations. This is a completely normal dynamic in the pharmaceutical sector.
Patent expirations are why drug companies are always on the lookout for new drugs. The problem is that patent expirations follow a set schedule, but drug development does not. Pfizer's drug pipeline isn't producing major new drugs right now, and it looks like it may have to work through a period in which new drugs won't fully offset revenue lost to patent expirations. This isn't uncommon, either, but investors are likely focusing on the short term rather than the long term when it comes to Pfizer.
#patent #yield #drug #expirations
Pfizer's stock rocketed higher during the coronavirus pandemic, as investors myopically focused on the company's COVID vaccine. When COVID turned out to be a less serious long-term threat than originally believed, Wall Street dumped Pfizer. At this point, the stock is down more than 50% from its 2021 high. That is a big part of the story behind the high yield.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
However, there's another piece that is more fundamental to the pharmaceutical industry. Like all drug makers, Pfizer's drugs receive time-limited patent protections. When patents expire, generic versions of the medications can be produced. That generally leads to a dramatic decline in revenue from Pfizer's drugs. Right now, Pfizer is facing down some notable patent expirations. This is a completely normal dynamic in the pharmaceutical sector.
Patent expirations are why drug companies are always on the lookout for new drugs. The problem is that patent expirations follow a set schedule, but drug development does not. Pfizer's drug pipeline isn't producing major new drugs right now, and it looks like it may have to work through a period in which new drugs won't fully offset revenue lost to patent expirations. This isn't uncommon, either, but investors are likely focusing on the short term rather than the long term when it comes to Pfizer.
#patent #yield #drug #expirations
14 days ago
Jenny Slatten's ALS battle has reached a heartbreaking new stage, with the beloved 90 Day Fiancé star now so weak that speaking has become painful—and her husband, Sumit Singh, has become her voice.
According to Page Six, the latest update came through a GoFundMe created to help cover Slatten's medical care in India, where Singh is caring for her full-time. According to Slatten's friend Penny, the 68-year-old reality star is "getting weaker by the day" while taking Edaravone and Riluzole, two medications intended to slow the progression of ALS. Penny said Slatten is also taking B12, melatonin and magnesium, but the treatments have left her drained.
"Jenny is getting weaker by the day," Penny wrote, adding that Slatten now "hardly speaks" because it hurts too much.
COMPLEX SHOP: Shop the brands you love, anytime and anywhere. Uncover what's next. Buy. Collect. Obsess.
"Sumit speaks more for her and is the main spokesperson for his wife," she continued. "Sumit is Jenny's main caregiver and doing a great job each day."
#sumit #shop
According to Page Six, the latest update came through a GoFundMe created to help cover Slatten's medical care in India, where Singh is caring for her full-time. According to Slatten's friend Penny, the 68-year-old reality star is "getting weaker by the day" while taking Edaravone and Riluzole, two medications intended to slow the progression of ALS. Penny said Slatten is also taking B12, melatonin and magnesium, but the treatments have left her drained.
"Jenny is getting weaker by the day," Penny wrote, adding that Slatten now "hardly speaks" because it hurts too much.
COMPLEX SHOP: Shop the brands you love, anytime and anywhere. Uncover what's next. Buy. Collect. Obsess.
"Sumit speaks more for her and is the main spokesperson for his wife," she continued. "Sumit is Jenny's main caregiver and doing a great job each day."
#sumit #shop
26 days ago
Without a signed, prospective contract, Medicaid treats family caregiver payments as gifts, exposing $60,000 in payments to a six-month nursing home ineligibility penalty.
A defensible care agreement must be signed before services begin, specify duties and market-rate pay, and be backed by time sheets and traceable payments.
At 20 documented hours per week, $2,500 monthly works out to roughly $29 per hour, defensible against the 2025 national median caregiver rate of $35.
Two retirees, same $1 million, same 4% rule, buy one finished with $1.4 million, the other hit $0 in 12 years. Our free reader guide explains the flaw that separated them, and the income-first method built to avoid it.
Picture a widow in her 80s who pays her adult daughter $2,500 a month for two years to handle bathing, meals, medications, driving to appointments, and overnight supervision. The care is real. The daughter cuts back her own job to provide it. One year later, mom breaks a hip, lands in a nursing home, and applies for institutional Medicaid. The caseworker pulls five years of bank statements, spots $60,000 in recurring payments to the daughter, and finds no signed agreement, no time sheets, no invoices. In that state, the agency treats every dollar as an uncompensated transfer, effectively a gift.
#signed #daughter
A defensible care agreement must be signed before services begin, specify duties and market-rate pay, and be backed by time sheets and traceable payments.
At 20 documented hours per week, $2,500 monthly works out to roughly $29 per hour, defensible against the 2025 national median caregiver rate of $35.
Two retirees, same $1 million, same 4% rule, buy one finished with $1.4 million, the other hit $0 in 12 years. Our free reader guide explains the flaw that separated them, and the income-first method built to avoid it.
Picture a widow in her 80s who pays her adult daughter $2,500 a month for two years to handle bathing, meals, medications, driving to appointments, and overnight supervision. The care is real. The daughter cuts back her own job to provide it. One year later, mom breaks a hip, lands in a nursing home, and applies for institutional Medicaid. The caseworker pulls five years of bank statements, spots $60,000 in recurring payments to the daughter, and finds no signed agreement, no time sheets, no invoices. In that state, the agency treats every dollar as an uncompensated transfer, effectively a gift.
#signed #daughter
1 month ago
(NewsNation) — A new study found that a rare but serious brain condition has been identified in a small number of people taking popular weight-loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound.
Wernicke encephalopathy is a rare neurological disorder caused by a severe deficiency of vitamin B1, also known as thiamine.
GLP-1 prescriptions for kids up more than 30,000% since 2019
Researchers identified 15 cases reported in 2023 and 2024 among people taking GLP-1 medications containing semaglutide, found in Ozempic and Wegovy, or tirzepatide, found in Mounjaro and Zepbound.
Vitamin B1 is essential for proper nerve function. Without enough of it, patients can develop confusion, problems with balance and coordination, and abnormal eye movements.
#zepbound #vitamin #identified
Wernicke encephalopathy is a rare neurological disorder caused by a severe deficiency of vitamin B1, also known as thiamine.
GLP-1 prescriptions for kids up more than 30,000% since 2019
Researchers identified 15 cases reported in 2023 and 2024 among people taking GLP-1 medications containing semaglutide, found in Ozempic and Wegovy, or tirzepatide, found in Mounjaro and Zepbound.
Vitamin B1 is essential for proper nerve function. Without enough of it, patients can develop confusion, problems with balance and coordination, and abnormal eye movements.
#zepbound #vitamin #identified
1 month ago
Investigators looking into Hayden Panettiere's death are reportedly focusing on a single pill they believe contained fentanyl.
Multiple law enforcement sources with direct knowledge of the investigation told TMZ that Panettiere took what she believed was oxycodone on the morning of Aug. 16, the day she died at age 36. Their working theory is that the pill had been laced with fentanyl.
The Greenville County Coroner's Office has not announced Panettiere's cause or manner of death, and toxicology results remain pending. TMZ's sources themselves cautioned that their theory still depends on those results.
The new report arrives as federal and local investigators try to determine where drugs and medications connected to Panettiere came from. The Los Angeles Times independently reported before TMZ's latest story that DEA agents and local authorities had been questioning people as part of that effort.
TMZ's sources allege that Panettiere had been obtaining black-market prescription drugs from a longtime source in Los Angeles before traveling to South Carolina on Aug. 15.
#panettiere #sources
Multiple law enforcement sources with direct knowledge of the investigation told TMZ that Panettiere took what she believed was oxycodone on the morning of Aug. 16, the day she died at age 36. Their working theory is that the pill had been laced with fentanyl.
The Greenville County Coroner's Office has not announced Panettiere's cause or manner of death, and toxicology results remain pending. TMZ's sources themselves cautioned that their theory still depends on those results.
The new report arrives as federal and local investigators try to determine where drugs and medications connected to Panettiere came from. The Los Angeles Times independently reported before TMZ's latest story that DEA agents and local authorities had been questioning people as part of that effort.
TMZ's sources allege that Panettiere had been obtaining black-market prescription drugs from a longtime source in Los Angeles before traveling to South Carolina on Aug. 15.
#panettiere #sources
1 month ago
On August 13, a federal appeals court ruled in favor of Gilead Sciences, Inc. (NASDAQ:GILD), upholding a preliminary injunction that bars the defendants from importing or facilitating the sale of foreign-market Gilead-branded medications in the US. The US Court of Appeals for the Fourth Circuit found that the differences between Gilead's HIV medication for the US market and the foreign versions being imported were "material, not theoretical." The controversy began in December 2024 when Gilead Sciences, Inc. (NASDAQ:GILD) filed suit against a number of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its best-selling HIV drug Biktarvy.
The dispute dates back to December 2024, when Gilead Sciences, Inc. (NASDAQ:GILD) sued a group of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its top-selling HIV drug Biktarvy. The lawsuit arose from a specific instance in which a patient in Maryland received the medicine in the mail from Turkey, with label instructions written in Turkish.
A federal district court in Baltimore ruled in Gilead's favor and ordered a preliminary injunction, determining that the company was likely to succeed on its Lanham Act trademark violation and unfair competition arguments. As the case continued, the injunction was increased to include new sellers like CanaRx, ElectRx, and ScriptSourcing. The defendants filed an appeal with the Fourth Circuit, and the district judge declined to suspend the injunction while the appeal was pending, thus the import restriction has been in effect the entire time. The recent ruling maintains the order rather than overturning it.
In court documents, Rx Valet stated that the Turkish-sourced Biktarvy was chemically identical to the US version, which was offered at a significantly higher price. Meritain, for its part, said that it has never supported getting non-FDA-approved pharmaceuticals from outside the US and denies the claims, despite being named as a defendant.
The Fourth Circuit rejected the defendants' main argument that the imported and domestic versions of Biktarvy are interchangeable. The court's judgment that the two versions differ materially, not just in packaging or labeling, but also in the quality-control protocols that each version goes through before reaching a patient, challenges the basic argument that these alternative funding programs have used to support their business model.
#gild
The dispute dates back to December 2024, when Gilead Sciences, Inc. (NASDAQ:GILD) sued a group of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its top-selling HIV drug Biktarvy. The lawsuit arose from a specific instance in which a patient in Maryland received the medicine in the mail from Turkey, with label instructions written in Turkish.
A federal district court in Baltimore ruled in Gilead's favor and ordered a preliminary injunction, determining that the company was likely to succeed on its Lanham Act trademark violation and unfair competition arguments. As the case continued, the injunction was increased to include new sellers like CanaRx, ElectRx, and ScriptSourcing. The defendants filed an appeal with the Fourth Circuit, and the district judge declined to suspend the injunction while the appeal was pending, thus the import restriction has been in effect the entire time. The recent ruling maintains the order rather than overturning it.
In court documents, Rx Valet stated that the Turkish-sourced Biktarvy was chemically identical to the US version, which was offered at a significantly higher price. Meritain, for its part, said that it has never supported getting non-FDA-approved pharmaceuticals from outside the US and denies the claims, despite being named as a defendant.
The Fourth Circuit rejected the defendants' main argument that the imported and domestic versions of Biktarvy are interchangeable. The court's judgment that the two versions differ materially, not just in packaging or labeling, but also in the quality-control protocols that each version goes through before reaching a patient, challenges the basic argument that these alternative funding programs have used to support their business model.
#gild
1 month ago
Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
A health savings account (HSA) is a type of account that lets you save — and potentially invest — for healthcare expenses while earning tax benefits along the way. Depending on your financial situation and immediate medical needs, an HSA can even be a valuable retirement planning tool. But HSAs aren't available to everyone. Continue reading to learn how HSAs work, their rules, and pros and cons.
A health savings account is a tax-advantaged account you can use to pay for qualifying medical expenses, including prescription medications, eyeglasses, doctor's visits, and more. Some HSAs function like a savings account, while others give you the option to invest your funds for future use.
HSAs are known for their triple tax advantage: You fund them with pre-tax dollars, your contributions grow tax-free, and withdrawals are tax-free as long as you use them for qualifying medical expenses. For this reason, HSAs can be a valuable retirement savings tool if you don't need the funds to pay for immediate medical needs.
Unlike flexible spending accounts (FSAs), HSA contributions don't expire at the end of the year. This means you can contribute to your account year after year without the need to "use it or lose it." HSAs aren't subject to required minimum distributions, either.
#account #medical #year
A health savings account (HSA) is a type of account that lets you save — and potentially invest — for healthcare expenses while earning tax benefits along the way. Depending on your financial situation and immediate medical needs, an HSA can even be a valuable retirement planning tool. But HSAs aren't available to everyone. Continue reading to learn how HSAs work, their rules, and pros and cons.
A health savings account is a tax-advantaged account you can use to pay for qualifying medical expenses, including prescription medications, eyeglasses, doctor's visits, and more. Some HSAs function like a savings account, while others give you the option to invest your funds for future use.
HSAs are known for their triple tax advantage: You fund them with pre-tax dollars, your contributions grow tax-free, and withdrawals are tax-free as long as you use them for qualifying medical expenses. For this reason, HSAs can be a valuable retirement savings tool if you don't need the funds to pay for immediate medical needs.
Unlike flexible spending accounts (FSAs), HSA contributions don't expire at the end of the year. This means you can contribute to your account year after year without the need to "use it or lose it." HSAs aren't subject to required minimum distributions, either.
#account #medical #year
1 month ago
Impax ***** et Management, based in London and specializing in sustainable investing, released its Q2 2026 investor letter for the "Impax US Sustainable Economy Fund". The letter can be downloaded here. The US Sustainable Economy portfolio outperformed the Russell 1000 in Q2 2026, with Institutional Class at 17.96%, Investor Class at 17.95%, and Class A at 17.92%, versus the index's 15.14%. Sector allocation and stock selection drove performance. The sustainability tools, including the Impax Sustainability Lens and Corporate Resilience framework, contributed positively. Equity markets rallied, with both the S&P 500 and Nasdaq reaching new highs before retreating. A key trend was rotation into AI and tech stocks, supported by mega-cap earnings and data center investments (US$750bn to US$1tn). In the second half of 2026, markets may remain volatile amid debates on AI adoption pace and economic momentum. However, growth tied to energy security and efficiency remains compelling, with demand for power, grid, and resource-efficient solutions supporting companies that benefit. The team focuses on businesses with strong growth, sound management, and attractive valuations, adjusting holdings as needed. This approach aims to build well-diversified, differentiated portfolios. Also, please check the fund's top five holdings for its best picks in 2026.
In its second-quarter 2026 investor letter, Impax US Sustainable Economy Fund highlighted Zoetis Inc. (NYSE:ZTS). Zoetis Inc. (NYSE:ZTS), an animal health company focused on animal health medications, vaccines, and diagnostic products, detracted from the Fund's performance during the quarter. On September 04, 2026, Zoetis Inc. (NYSE:ZTS) closed at $75.81 per share. Over the past month, Zoetis Inc. (NYSE:ZTS) returned 1.31%, but its shares are down 50.04% over the past year. Zoetis Inc. (NYSE:ZTS) has a market capitalization of $31.33 billion.
Impax US Sustainable Economy Fund stated the following regarding Zoetis Inc. (NYSE:ZTS) in its Q2 2026 investor letter:
"Zoetis Inc. (NYSE:ZTS) (Pharmaceuticals, Health Care) is owned for its attractive sustainability opportunity profile in areas including Wellbeing and Evolving Health Care Challenge, as well as its strong governance profile. The stock declined sharply in the quarter following a downward revision to near-term earnings guidance. Sales of Librela, the company's key canine arthritis pain management product, continued to face headwinds from safety perception concerns among some veterinarians, and management indicated that the ramp-up of next-generation product launches would extend into the following year."
#economy #Health
In its second-quarter 2026 investor letter, Impax US Sustainable Economy Fund highlighted Zoetis Inc. (NYSE:ZTS). Zoetis Inc. (NYSE:ZTS), an animal health company focused on animal health medications, vaccines, and diagnostic products, detracted from the Fund's performance during the quarter. On September 04, 2026, Zoetis Inc. (NYSE:ZTS) closed at $75.81 per share. Over the past month, Zoetis Inc. (NYSE:ZTS) returned 1.31%, but its shares are down 50.04% over the past year. Zoetis Inc. (NYSE:ZTS) has a market capitalization of $31.33 billion.
Impax US Sustainable Economy Fund stated the following regarding Zoetis Inc. (NYSE:ZTS) in its Q2 2026 investor letter:
"Zoetis Inc. (NYSE:ZTS) (Pharmaceuticals, Health Care) is owned for its attractive sustainability opportunity profile in areas including Wellbeing and Evolving Health Care Challenge, as well as its strong governance profile. The stock declined sharply in the quarter following a downward revision to near-term earnings guidance. Sales of Librela, the company's key canine arthritis pain management product, continued to face headwinds from safety perception concerns among some veterinarians, and management indicated that the ramp-up of next-generation product launches would extend into the following year."
#economy #Health
1 month ago
Ro Khanna is a Democratic congressman from California whose stock picks keep making headlines. His latest financial disclosures show steady buying in two names through June and July.
Uber Technologies, Inc. (NYSE:UBER) shows up more than any other stock in the filing. Khanna's disclosures list several separate Uber purchases between June 15 and July 29, with no sales in that stretch. Uber is down about 18% over the past year.
Chewy Inc. (NYSE:CHWY) is the second name. The filing shows nine Chewy purchases between July 13 and July 30.
Chewy is down about 40% over the past year and 30% so far this year. Is this a potential opportunity to buy the stock on the dip? Let's **** yze.
Chewy, Inc. (NYSE:CHWY) sells pet food, treats, supplies and medications online. The business runs on Autoship, a subscription program where customers set up recurring deliveries.
#chewy #chwy #shows
Uber Technologies, Inc. (NYSE:UBER) shows up more than any other stock in the filing. Khanna's disclosures list several separate Uber purchases between June 15 and July 29, with no sales in that stretch. Uber is down about 18% over the past year.
Chewy Inc. (NYSE:CHWY) is the second name. The filing shows nine Chewy purchases between July 13 and July 30.
Chewy is down about 40% over the past year and 30% so far this year. Is this a potential opportunity to buy the stock on the dip? Let's **** yze.
Chewy, Inc. (NYSE:CHWY) sells pet food, treats, supplies and medications online. The business runs on Autoship, a subscription program where customers set up recurring deliveries.
#chewy #chwy #shows
1 month ago
Joe Amabile paid a heartfelt tribute to his wife, Serena Pitt, on their anniversary as he continues to recover from brain tumor surgery. The former Bachelor in Paradise star praised his wife for supporting him through both the good and the difficult moments.
Joe, who became known as Grocery Store Joe during Season 14 of The Bachelorette, marked their three-year anniversary with a special post on September 2. The 40-year-old wrote on Instagram that Pitt is "the most beautiful, caring, perfect" person. "These past few months have been pretty tough, to say the least. You have been there with me every single step of the way, taking in all the good and the bad news. You cried alone in our bedroom because you didn't want to bring me down," the Dancing With the Stars alum expressed.
Continuing his post, Joe praised Serena for standing by him throughout his recovery. He said she took care of everything from cooking and cleaning to attending his doctor's appointments. She also managed his medications and woke up with him in the middle of the night. Joe said he felt incredibly lucky to have Serena as his wife, partner, and best friend. He ended the heartfelt message by telling her he loved her "forever and always."
Joe and Serena got engaged on Bachelor in Paradise season 7 in 2021. They first tied the knot at a New York City courthouse on October 27, 2022. They held a second, larger wedding celebration with loved ones in Charleston on September 2, 2023.
The former reality star first revealed the diagnosis on July 13 in an Instagram video. He said a full-body MRI scan through Prenuvo led doctors to discover an early-stage glioma. He explained that he later underwent a brain MRI. The scan showed a blueberry-sized lesion in his brain that appeared to be a glioma, which is a type of tumor.
#wife #brain #season #heartfelt
Joe, who became known as Grocery Store Joe during Season 14 of The Bachelorette, marked their three-year anniversary with a special post on September 2. The 40-year-old wrote on Instagram that Pitt is "the most beautiful, caring, perfect" person. "These past few months have been pretty tough, to say the least. You have been there with me every single step of the way, taking in all the good and the bad news. You cried alone in our bedroom because you didn't want to bring me down," the Dancing With the Stars alum expressed.
Continuing his post, Joe praised Serena for standing by him throughout his recovery. He said she took care of everything from cooking and cleaning to attending his doctor's appointments. She also managed his medications and woke up with him in the middle of the night. Joe said he felt incredibly lucky to have Serena as his wife, partner, and best friend. He ended the heartfelt message by telling her he loved her "forever and always."
Joe and Serena got engaged on Bachelor in Paradise season 7 in 2021. They first tied the knot at a New York City courthouse on October 27, 2022. They held a second, larger wedding celebration with loved ones in Charleston on September 2, 2023.
The former reality star first revealed the diagnosis on July 13 in an Instagram video. He said a full-body MRI scan through Prenuvo led doctors to discover an early-stage glioma. He explained that he later underwent a brain MRI. The scan showed a blueberry-sized lesion in his brain that appeared to be a glioma, which is a type of tumor.
#wife #brain #season #heartfelt
1 month ago
Golf legend Tiger Woods was arrested in March for yet another vehicular accident. Woods agreed to a Breathalyzer test that showed no signs of alcohol, but he refused a urine test and showed signs of impairment during the ordeal.
Officers found two painkiller pills in his pocket, and he told deputies he had taken "a few" prescription medications earlier that day. Later, Woods pleaded not guilty to misdemeanor charges of driving under the influence and refusal to submit to testing.
Recently, Woods announced he planned to change his not guilty plea, according to court documents filed Tuesday. Woods was scheduled to appear in court on September 8th but is now expected on Wednesday morning for a plea conference.
The golf legend has been involved in a few other crashes over the years, all of which have stunted his illustrious career. In 2021, he survived a crash in Los Angeles so severe that doctors considered amputating his leg. Woods was not charged with any crimes as authorities determined the crash was caused by excessive speed and not impairment. On the other hand, in 2009, Woods crashed into a fire hydrant and a tree outside of his residence around 2:00 a.m. Police suspected Woods was under the influence or impaired by medication, but no actual charges followed.
Woods has had to bow out of golf due to several back surgeries and lower-body injuries that have affected his mobility. As a result, Woods has battled with prescribed substance dependency. As of June, he formally stepped away from the game and traveled outside of the United States to seek treatment at an inpatient treatment facility.
#golf #signs #charges
Officers found two painkiller pills in his pocket, and he told deputies he had taken "a few" prescription medications earlier that day. Later, Woods pleaded not guilty to misdemeanor charges of driving under the influence and refusal to submit to testing.
Recently, Woods announced he planned to change his not guilty plea, according to court documents filed Tuesday. Woods was scheduled to appear in court on September 8th but is now expected on Wednesday morning for a plea conference.
The golf legend has been involved in a few other crashes over the years, all of which have stunted his illustrious career. In 2021, he survived a crash in Los Angeles so severe that doctors considered amputating his leg. Woods was not charged with any crimes as authorities determined the crash was caused by excessive speed and not impairment. On the other hand, in 2009, Woods crashed into a fire hydrant and a tree outside of his residence around 2:00 a.m. Police suspected Woods was under the influence or impaired by medication, but no actual charges followed.
Woods has had to bow out of golf due to several back surgeries and lower-body injuries that have affected his mobility. As a result, Woods has battled with prescribed substance dependency. As of June, he formally stepped away from the game and traveled outside of the United States to seek treatment at an inpatient treatment facility.
#golf #signs #charges
1 month ago
CBS NFL ******* yst and former Dallas Cowboys quarterback Tony Romo has pleaded no contest to a charge of operating while intoxicated and has issued a statement apologizing for the actions that led to his July arrest.
Romo was arrested July 23 following a traffic stop as he was driving south on Interstate 43 in Wisconsin. CBS has since placed him on leave from his role as its lead NFL ******* yst.
According to Milwaukee County court records, Romo lost his driving privileges for six months and was ordered to complete an alcohol ******* sment program. He also owes $834. An interlock device must be installed on any vehicle owned or operated by Romo or registered to his name, and that order will remain in effect for at least one year after he is issued a license.
"The past month has been difficult, but it has also been personally significant," Romo said in a statement on Instagram. "It has required me to confront and own my mistakes fully — to the Lord, to myself, to my family and now to the public."
Romo said the multiple back surgeries that led to his retirement as a player "left me with constant, debilitating pain." He noted that the pain "led to a dependence on pain medication, and my efforts to get off those medications led to an over-reliance on alcohol."
#romo #issued #driving
Romo was arrested July 23 following a traffic stop as he was driving south on Interstate 43 in Wisconsin. CBS has since placed him on leave from his role as its lead NFL ******* yst.
According to Milwaukee County court records, Romo lost his driving privileges for six months and was ordered to complete an alcohol ******* sment program. He also owes $834. An interlock device must be installed on any vehicle owned or operated by Romo or registered to his name, and that order will remain in effect for at least one year after he is issued a license.
"The past month has been difficult, but it has also been personally significant," Romo said in a statement on Instagram. "It has required me to confront and own my mistakes fully — to the Lord, to myself, to my family and now to the public."
Romo said the multiple back surgeries that led to his retirement as a player "left me with constant, debilitating pain." He noted that the pain "led to a dependence on pain medication, and my efforts to get off those medications led to an over-reliance on alcohol."
#romo #issued #driving
2 months ago
Kelley Wolf apologized to her ex-husband, actor Scott Wolf, saying she experienced "breakthrough drug-induced mania with psychosis," as she believed she was in the CIA and running for president.
"Wow ... I have taken about 100 deep breaths to write this," Kelley posted Saturday on Instagram. "How do I even start. It's been a year since I recognized what everyone around me could see: I was not well, and I needed help."
Buzz: 'SNL' Alum-Turned-MAGA Cheerleader Is Getting Divorced
She continued: "I felt like my brain had been hijacked, and the world was moving at the speed of a freight train. It turns out that is exactly what happened, but I didn't know it."
Kelley, who rose to fame on 2000's "The Real World: New Orleans," said she was "completely delusional" for a time and her "breakthrough drug-induced mania with psychosis," was caused by "stress, past trauma, hormonal shifts, and hallucinogens mixed with prescribed medications."
#mania #psychosis
"Wow ... I have taken about 100 deep breaths to write this," Kelley posted Saturday on Instagram. "How do I even start. It's been a year since I recognized what everyone around me could see: I was not well, and I needed help."
Buzz: 'SNL' Alum-Turned-MAGA Cheerleader Is Getting Divorced
She continued: "I felt like my brain had been hijacked, and the world was moving at the speed of a freight train. It turns out that is exactly what happened, but I didn't know it."
Kelley, who rose to fame on 2000's "The Real World: New Orleans," said she was "completely delusional" for a time and her "breakthrough drug-induced mania with psychosis," was caused by "stress, past trauma, hormonal shifts, and hallucinogens mixed with prescribed medications."
#mania #psychosis
2 months ago
The Los Angeles County Medical Examiner's full autopsy report on late Memphis Grizzlies veteran forward and former Phoenix Desert Vista standout Brandon Clarke was released Monday, Aug. 24. Clarke had cocaine, heroin, oxycodone, and multiple other medications "within therapeutic levels," per the report obtained by USA Today Sports.
Clarke's roommate told officials that Clarke had a "history of drug use" and underwent multiple rehabilitation stints for drug addiction, according to the report's synopsis.
Clarke died at his San Fernando Valley residence on May 11. He was 29 years old. The cause of death was an accidental overdose from the "effects of heroin and cocaine" in Clarke's system, which matched the medical examiner's initial statement about Clarke on Aug. 7.
Los Angeles Fire Department officials listed in the incident's early reports that he was found unresponsive and declared dead at the scene.
Drug paraphernalia was found at Clarke's home, according to the synopsis report. That included "vape devices, cannabis products, prescription medications, injectable peptides, syringes, a box of Narcan, blister packets of medications, vitamins and other medical evidence." Also, there was a plate with an "unknown white powdery substance and a hotel keycard" found in the kitchen.
#medical #drug
Clarke's roommate told officials that Clarke had a "history of drug use" and underwent multiple rehabilitation stints for drug addiction, according to the report's synopsis.
Clarke died at his San Fernando Valley residence on May 11. He was 29 years old. The cause of death was an accidental overdose from the "effects of heroin and cocaine" in Clarke's system, which matched the medical examiner's initial statement about Clarke on Aug. 7.
Los Angeles Fire Department officials listed in the incident's early reports that he was found unresponsive and declared dead at the scene.
Drug paraphernalia was found at Clarke's home, according to the synopsis report. That included "vape devices, cannabis products, prescription medications, injectable peptides, syringes, a box of Narcan, blister packets of medications, vitamins and other medical evidence." Also, there was a plate with an "unknown white powdery substance and a hotel keycard" found in the kitchen.
#medical #drug
2 months ago
(NEXSTAR) – From unexpected babies to "Ozempic teeth," the ultra-popular class of GLP-1 medications is turning out to have a few unanticipated side effects. Emerging research shows the drugs, which have proven effective in treating obesity and diabetes, may also be useful in treating addiction.
The medications' full potential is coming to light as more people are prescribed a GLP-1, which includes the brand names Ozempic, Mounjaro, Wegovy and Zepbound. As 15% of Americans say they've tried a GLP-1, researchers are learning more about how it impacts all aspects of life, not just diet.
"This drug has been available in the medical community since 2005," said Dr. Eugene Lucas, professor and coordinator of the Psychiatric Mental Health Nurse Practitioner Program at Wilkes University. "And over time, when physicians are ordering these medications for people with obesity, diabetes, they're finding that if they have a concurrent addictive disorder, and specifically alcohol, that they're either cutting back or stopping their alcohol use."
A large study of more than 200,000 people in Sweden found using a GLP-1 drug was ***** ociated with a decreased risk of hospitalization from alcohol use disorder.
Another study by researchers at the Washington University School of Medicine, which looked at 600,000 veterans with type 2 diabetes, found the medications were tied to a lower risk of developing any kind of substance use disorder.
#medications #diabetes #disorder #university
The medications' full potential is coming to light as more people are prescribed a GLP-1, which includes the brand names Ozempic, Mounjaro, Wegovy and Zepbound. As 15% of Americans say they've tried a GLP-1, researchers are learning more about how it impacts all aspects of life, not just diet.
"This drug has been available in the medical community since 2005," said Dr. Eugene Lucas, professor and coordinator of the Psychiatric Mental Health Nurse Practitioner Program at Wilkes University. "And over time, when physicians are ordering these medications for people with obesity, diabetes, they're finding that if they have a concurrent addictive disorder, and specifically alcohol, that they're either cutting back or stopping their alcohol use."
A large study of more than 200,000 people in Sweden found using a GLP-1 drug was ***** ociated with a decreased risk of hospitalization from alcohol use disorder.
Another study by researchers at the Washington University School of Medicine, which looked at 600,000 veterans with type 2 diabetes, found the medications were tied to a lower risk of developing any kind of substance use disorder.
#medications #diabetes #disorder #university
2 months ago
Amazon plans to dramatically expand its Prime Air drone delivery service, saying it expects to reach nearly 500 U.S. cities and towns by the end of 2026 as retailers race to make airborne deliveries a larger part of everyday shopping.
The expansion would increase Prime Air's footprint sixfold, giving tens of millions more customers access to drone deliveries. Amazon said eligible shoppers can order millions of products, including groceries, electronics, medications and household essentials, with deliveries arriving in as fast as 30 minutes.
The announcement comes as the drone delivery industry appears poised for rapid growth. The Federal Aviation Administration (FAA) has proposed rules that would make it easier for certified operators to fly drones beyond a pilot's visual line of sight, a change companies say could significantly reduce costs and allow services to expand more quickly, according to Reuters.
Here's what to know about Amazon's Prime Air expansion, including where drone delivery is available and where it's headed next.
Prime Air currently operates from 11 delivery sites serving metro areas including Phoenix; Tampa, Florida; Kansas City, Kansas; Baton Rouge, Louisiana; Detroit; Omaha, Nebraska; Houston; Dallas; San Antonio; and Waco, Texas.
#delivery #amazon #expansion
The expansion would increase Prime Air's footprint sixfold, giving tens of millions more customers access to drone deliveries. Amazon said eligible shoppers can order millions of products, including groceries, electronics, medications and household essentials, with deliveries arriving in as fast as 30 minutes.
The announcement comes as the drone delivery industry appears poised for rapid growth. The Federal Aviation Administration (FAA) has proposed rules that would make it easier for certified operators to fly drones beyond a pilot's visual line of sight, a change companies say could significantly reduce costs and allow services to expand more quickly, according to Reuters.
Here's what to know about Amazon's Prime Air expansion, including where drone delivery is available and where it's headed next.
Prime Air currently operates from 11 delivery sites serving metro areas including Phoenix; Tampa, Florida; Kansas City, Kansas; Baton Rouge, Louisiana; Detroit; Omaha, Nebraska; Houston; Dallas; San Antonio; and Waco, Texas.
#delivery #amazon #expansion
2 months ago
Tess Holliday shared a video addressing recent body-shaming comments she's received and her confident and empowering response to critics
The model and activist has previously shut down critics suggesting she take weight-loss medications like Ozempic
Holliday continues to advocate for body positivity and self-confidence, despite ongoing criticism about her appearance
Online criticism is not interfering with Tess Holliday's confidence.
On Thursday, Aug. 13, the model and body activist, 41, posted a video on TikTok listing some of the recent body-shaming comments she's received — "You're so fat," "Ew disgusting," "I'm just worried about your health," "Lose weight," "Ozempic exists," "Cover up" and "No one wants this."
#comments #model
The model and activist has previously shut down critics suggesting she take weight-loss medications like Ozempic
Holliday continues to advocate for body positivity and self-confidence, despite ongoing criticism about her appearance
Online criticism is not interfering with Tess Holliday's confidence.
On Thursday, Aug. 13, the model and body activist, 41, posted a video on TikTok listing some of the recent body-shaming comments she's received — "You're so fat," "Ew disgusting," "I'm just worried about your health," "Lose weight," "Ozempic exists," "Cover up" and "No one wants this."
#comments #model
2 months ago
Eli Lilly and Company (NYSE:LLY) cleared a notable regulatory hurdle on August 10, when Britain's drug regulator authorized the company's oral GLP-1 drug orforglipron, becoming the first country in Europe to approve the pill. Shares of LLY increased more than 2% in response to the announcement, a modest but insightful reaction for a company whose weight-loss franchise has become the single most important driver of its market value.
The UK's Medicines and Healthcare Products Regulatory Agency approved orforglipron, offered under the brand name Foundayo, for weight loss and maintenance in obese adults, as well as select overweight individuals with at least one weight-related health condition. The approval also addresses increasing blood sugar control in people with type 2 diabetes.
What sets Foundayo apart from Lilly's other weight-loss medications, as well as the majority of the GLP-1 category in general, is the format. Unlike injectable drugs like Lilly's Zepbound or Novo Nordisk A/S (NYSE:NVO)'s Ozempic, Foundayo is a small, non-peptide GLP-1 receptor agonist that is taken as a single daily tablet. It can also be taken at any time with no food or water restrictions, making it a far more convenient regimen than some oral peptide alternatives that require fasting windows around dosing.
The clinical data that supports the approval is strong. In the ATTAIN-1 trial, which tracked 3,127 individuals with obesity for 72 weeks, participants on the 36 mg dose lost an average of 11.2% of their body weight, as opposed to 2.1% on placebo, and more than half of those on that dose lost at least 10%.
The authorization is crucial, but it is not the final step. Foundayo is not currently available through the NHS in the UK, and the drug's journey to that larger market is through the National Institute for Health and Care Excellence, which is completing its own cost-effectiveness study, with a decision expected on November 18. Until NICE decides, UK patients seeking the medicine will have to pay out of pocket or get it privately, a scenario that is already playing out with competing products in the category.
#foundayo #loss #NYSE #regulatory
The UK's Medicines and Healthcare Products Regulatory Agency approved orforglipron, offered under the brand name Foundayo, for weight loss and maintenance in obese adults, as well as select overweight individuals with at least one weight-related health condition. The approval also addresses increasing blood sugar control in people with type 2 diabetes.
What sets Foundayo apart from Lilly's other weight-loss medications, as well as the majority of the GLP-1 category in general, is the format. Unlike injectable drugs like Lilly's Zepbound or Novo Nordisk A/S (NYSE:NVO)'s Ozempic, Foundayo is a small, non-peptide GLP-1 receptor agonist that is taken as a single daily tablet. It can also be taken at any time with no food or water restrictions, making it a far more convenient regimen than some oral peptide alternatives that require fasting windows around dosing.
The clinical data that supports the approval is strong. In the ATTAIN-1 trial, which tracked 3,127 individuals with obesity for 72 weeks, participants on the 36 mg dose lost an average of 11.2% of their body weight, as opposed to 2.1% on placebo, and more than half of those on that dose lost at least 10%.
The authorization is crucial, but it is not the final step. Foundayo is not currently available through the NHS in the UK, and the drug's journey to that larger market is through the National Institute for Health and Care Excellence, which is completing its own cost-effectiveness study, with a decision expected on November 18. Until NICE decides, UK patients seeking the medicine will have to pay out of pocket or get it privately, a scenario that is already playing out with competing products in the category.
#foundayo #loss #NYSE #regulatory
2 months ago
Originally appeared on E! Online
For more than half a decade, Chrissy Metz was determined to avoid the big three.
As in Ozempic, Mounjaro, Wegovy...
Of course, the list of GLP-1 weight loss injectables and the public's ability to rattle them off has vastly expanded since news of oh-oh-oh Ozempic shot to the top of public consciousness in 2023.
By then, the This Is Us star was already pretty well-versed in the type 2 diabetes medications that can be prescribed for weight loss. And also quite averse.
#weight
For more than half a decade, Chrissy Metz was determined to avoid the big three.
As in Ozempic, Mounjaro, Wegovy...
Of course, the list of GLP-1 weight loss injectables and the public's ability to rattle them off has vastly expanded since news of oh-oh-oh Ozempic shot to the top of public consciousness in 2023.
By then, the This Is Us star was already pretty well-versed in the type 2 diabetes medications that can be prescribed for weight loss. And also quite averse.
#weight
2 months ago
Chrissy Metz is opening up about her decision to start taking a GLP-1.
In a new interview with People, the This Is Us alum, 45, said that after years of trying different diets and fitness routines that didn't work, she opted for weight loss medication.
"I just wanted to take care of myself," Metz said.
"I'm not getting any younger. I'm in perimenopause, and there were obesity issues within my family and with my father, and I felt like I've tried so many modalities, whether it was diets or therapy, and none of it really worked for me," she continued.
Metz was skeptical at first, however, about starting a GLP-1, which, per the Cleveland Clinic, are "medications that help lower blood sugar levels and promote weight loss." In addition to being worried that the popular weight loss drugs wouldn't work for her, Metz was scared she would experience some of the horrible side effects often **** ociated with taking the medication, including nausea, vomiting, diarrhea and constipation, per Harvard Health.
#weight #people
In a new interview with People, the This Is Us alum, 45, said that after years of trying different diets and fitness routines that didn't work, she opted for weight loss medication.
"I just wanted to take care of myself," Metz said.
"I'm not getting any younger. I'm in perimenopause, and there were obesity issues within my family and with my father, and I felt like I've tried so many modalities, whether it was diets or therapy, and none of it really worked for me," she continued.
Metz was skeptical at first, however, about starting a GLP-1, which, per the Cleveland Clinic, are "medications that help lower blood sugar levels and promote weight loss." In addition to being worried that the popular weight loss drugs wouldn't work for her, Metz was scared she would experience some of the horrible side effects often **** ociated with taking the medication, including nausea, vomiting, diarrhea and constipation, per Harvard Health.
#weight #people
2 months ago
Coleen Nolan has shown off the results of her 3.5-stone weight loss after dropping from a size 20 to a size 14 and reaching the point where she says she no longer wants the number on the scale to fall.
The 61-year-old Loose Women star has documented her transformation throughout 2026 after partnering with clinical weight-loss company Voy. She has said she now has more energy, an improved back and greater confidence in the clothes she wears.
The partnership has also generated speculation because Voy offers prescription weight-loss treatments, including injectable medications. Nolan had previously expressed reservations about weight-loss jabs, but she has never publicly said that she personally used Mounjaro, Wegovy or another injection to achieve her 3.5-stone loss.
What Nolan has said is that a pre-diabetes diagnosis changed how seriously she viewed her health after years of yo-yo dieting. She joined Voy looking for a longer-term approach and has since said she has reached a weight she is happy to maintain.
"I feel so much better health-wise," she told The Sun. "My back's improved, I've got more energy. And confidence-wise, of course it helps." Nolan also made clear that she was no longer trying to continue losing weight.
#stone
The 61-year-old Loose Women star has documented her transformation throughout 2026 after partnering with clinical weight-loss company Voy. She has said she now has more energy, an improved back and greater confidence in the clothes she wears.
The partnership has also generated speculation because Voy offers prescription weight-loss treatments, including injectable medications. Nolan had previously expressed reservations about weight-loss jabs, but she has never publicly said that she personally used Mounjaro, Wegovy or another injection to achieve her 3.5-stone loss.
What Nolan has said is that a pre-diabetes diagnosis changed how seriously she viewed her health after years of yo-yo dieting. She joined Voy looking for a longer-term approach and has since said she has reached a weight she is happy to maintain.
"I feel so much better health-wise," she told The Sun. "My back's improved, I've got more energy. And confidence-wise, of course it helps." Nolan also made clear that she was no longer trying to continue losing weight.
#stone
2 months ago
(NewsNation) — Retirees shouldn't be alarmed by the ending of a Biden-era Medicare premium subsidy program, an industry expert says.
Last week, the Trump administration said it would move to shutter the program, subsequently bringing to an end Medicare Part D subsidies at the cessation of 2026.
Medicare Part D is optional prescription drug coverage offered by private insurance companies to help people with Medicare pay for brand-name and generic medications.
It is available as a stand-alone plan to add to original Medicare or as part of a bundled Medicare Advantage plan.
"While headlines about the end of Medicare's premium stabilization program may sound alarming, retirees shouldn't confuse that change with a loss of Medicare prescription drug coverage," Chris Maikels, senior actuary and strategy leader of retiree solutions at Aptia Group, told NewsNation.
#coverage
Last week, the Trump administration said it would move to shutter the program, subsequently bringing to an end Medicare Part D subsidies at the cessation of 2026.
Medicare Part D is optional prescription drug coverage offered by private insurance companies to help people with Medicare pay for brand-name and generic medications.
It is available as a stand-alone plan to add to original Medicare or as part of a bundled Medicare Advantage plan.
"While headlines about the end of Medicare's premium stabilization program may sound alarming, retirees shouldn't confuse that change with a loss of Medicare prescription drug coverage," Chris Maikels, senior actuary and strategy leader of retiree solutions at Aptia Group, told NewsNation.
#coverage
2 months ago
Chris Bosh revealed that he suffered a blood clot that almost killed him in January
Bosh said he "came back to life" after the scary episode
Now he's urging others to take care of their health and stay on top of any necessary medications
Chris Bosh is spreading the message about the dangers of blood clots.
The two-time NBA champ, 42, is relaying a personal medical emergency in the hopes that others ****** e to the issue — including San Antonio Spurs star Victor Wembanyama — will pay attention to their health.
#others #january
Bosh said he "came back to life" after the scary episode
Now he's urging others to take care of their health and stay on top of any necessary medications
Chris Bosh is spreading the message about the dangers of blood clots.
The two-time NBA champ, 42, is relaying a personal medical emergency in the hopes that others ****** e to the issue — including San Antonio Spurs star Victor Wembanyama — will pay attention to their health.
#others #january
2 months ago
Interested in Loblaw Companies Limited? Here are five stocks we like better.
Loblaw delivered solid Q2 growth: Revenue rose 4.1% to C$15.3 billion, adjusted EBITDA increased 5.1% to C$1.9 billion, and adjusted diluted EPS climbed 11.9% to C$0.66.
Discount grocery, pharmacy and e-commerce led momentum. Hard-discount comparable sales grew nearly 4%, drug retail sales increased 6.1%, and online sales rose 19.3%; management also sees significant longer-term growth potential from generic GLP-1 medications.
Management maintained an upbeat outlook and boosted shareholder returns. Loblaw reaffirmed high-single-digit adjusted EPS growth for 2026, raised expected share repurchases to C$2.1 billion, and expects store expansion and distribution-center costs to ease in the second half.
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
#adjusted #sales
Loblaw delivered solid Q2 growth: Revenue rose 4.1% to C$15.3 billion, adjusted EBITDA increased 5.1% to C$1.9 billion, and adjusted diluted EPS climbed 11.9% to C$0.66.
Discount grocery, pharmacy and e-commerce led momentum. Hard-discount comparable sales grew nearly 4%, drug retail sales increased 6.1%, and online sales rose 19.3%; management also sees significant longer-term growth potential from generic GLP-1 medications.
Management maintained an upbeat outlook and boosted shareholder returns. Loblaw reaffirmed high-single-digit adjusted EPS growth for 2026, raised expected share repurchases to C$2.1 billion, and expects store expansion and distribution-center costs to ease in the second half.
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
#adjusted #sales
3 months ago
Platinum ****** et Management, an investment management company, released its Q2 2026 investor letter for "Platinum International Brands Fund". A copy of the letter can be downloaded here. The fund returned over 4% in the quarter but lost 14% over the past year, primarily due to the dominance of tech stocks amid an AI investment boom. Consumer-focused sectors underperformed due to weak sentiment and challenges such as high interest rates and rising oil prices, which have contributed to record-low consumer confidence. However, the fund's holdings remain fundamentally strong, with top holdings averaging 13% sales growth and 19% profit growth. The letter noted that positive developments include resumed job growth, reduced oil prices, and easing fiscal policy, which potentially enhance consumer sentiment. In addition, please check the Fund's top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Platinum International Brands Fund highlighted Zoetis Inc. (NYSE:ZTS). Zoetis Inc. (NYSE:ZTS), an animal health company focused on animal health medications, vaccines, and diagnostic products, detracted from the Fund's performance during the quarter. On July 28, 2026, Zoetis Inc. (NYSE:ZTS) closed at $77.51 per share. One-month return of Zoetis Inc. (NYSE:ZTS) was 6.98%, and its shares lost 47.91% over the past 52 weeks. Zoetis Inc. (NYSE:ZTS) has a market capitalization of about $32.49 billion.
Platinum International Brands Fund stated the following regarding Zoetis Inc. (NYSE:ZTS) in its Q2 2026 investor update:
"Our worst performer was Zoetis (-35%). Simply, we got this wrong. Zoetis Inc. (NYSE:ZTS) makes medicines for pets and livestock and has long been the great innovator of its field, having pioneered and dominated the huge markets for canine dermatology and three-in-one parasiticides.
Unfortunately, its rivals have caught up and its commercial response has disappointed. In fairness, it likely expected its promising new arthritis treatment to comfortably offset any erosion. However, a social media scare campaign derailed its US launch largely because their commercial response was again inadequate.
#brands #investor
In its Q2 2026 investor letter, Platinum International Brands Fund highlighted Zoetis Inc. (NYSE:ZTS). Zoetis Inc. (NYSE:ZTS), an animal health company focused on animal health medications, vaccines, and diagnostic products, detracted from the Fund's performance during the quarter. On July 28, 2026, Zoetis Inc. (NYSE:ZTS) closed at $77.51 per share. One-month return of Zoetis Inc. (NYSE:ZTS) was 6.98%, and its shares lost 47.91% over the past 52 weeks. Zoetis Inc. (NYSE:ZTS) has a market capitalization of about $32.49 billion.
Platinum International Brands Fund stated the following regarding Zoetis Inc. (NYSE:ZTS) in its Q2 2026 investor update:
"Our worst performer was Zoetis (-35%). Simply, we got this wrong. Zoetis Inc. (NYSE:ZTS) makes medicines for pets and livestock and has long been the great innovator of its field, having pioneered and dominated the huge markets for canine dermatology and three-in-one parasiticides.
Unfortunately, its rivals have caught up and its commercial response has disappointed. In fairness, it likely expected its promising new arthritis treatment to comfortably offset any erosion. However, a social media scare campaign derailed its US launch largely because their commercial response was again inadequate.
#brands #investor
3 months ago
By Jody Godoy
July 29 (Reuters) - The U.S. Federal Trade Commission sued Hims & Hers on Wednesday alleging the telehealth platform shared users' health data with online advertisers, despite promising privacy, and engaged in deceptive billing and cancellation practices.
Users' sensitive health information was shared with online advertising companies including Meta Platforms and Snap despite the company leading customers to believe their data was private, the FTC alleged in the lawsuit filed along with Los Angeles County and Utah.
Hims & Hers stock added to losses after the news and was trading down around 12%.
Hims & Hers is one of the largest telehealth players in the market for weight loss drugs. The company offers telehealth appointments and prescriptions for erectile dysfunction, hair loss, and mental health medications, which it ships straight to customers.
#Health #despite #company
July 29 (Reuters) - The U.S. Federal Trade Commission sued Hims & Hers on Wednesday alleging the telehealth platform shared users' health data with online advertisers, despite promising privacy, and engaged in deceptive billing and cancellation practices.
Users' sensitive health information was shared with online advertising companies including Meta Platforms and Snap despite the company leading customers to believe their data was private, the FTC alleged in the lawsuit filed along with Los Angeles County and Utah.
Hims & Hers stock added to losses after the news and was trading down around 12%.
Hims & Hers is one of the largest telehealth players in the market for weight loss drugs. The company offers telehealth appointments and prescriptions for erectile dysfunction, hair loss, and mental health medications, which it ships straight to customers.
#Health #despite #company
3 months ago
An estimated 21.5 million additional adults in the United States may now be eligible for statins under updated cholesterol treatment guidelines, according to a new study.
The researchers aimed to estimate how many adults in the US would be considered eligible for statin therapy under the new 2026 blood cholesterol guidelines issued by the American Heart **** ociation, the American College of Cardiology and nine partnering medical societies, compared with the previous 2018 guidelines.
The **** ysis, published July 20 in the journal JAMA, found that the changes could bring the total number of Americans eligible for statins, medications that lower cholesterol, to about 87.5 million people, or more than half of adults ages 30 to 79.
What prompted this major expansion, and does being eligible mean that someone should immediately begin taking medication? To help us understand the study and what patients should discuss with their healthcare providers, I spoke with CNN wellness expert Dr. Leana Wen. Wen is an emergency physician and clinical **** ociate professor at George Washington University. She previously served as Baltimore's health commissioner.
CNN: Who are the millions of Americans who are newly eligible for statins and why?
#statins #cholesterol
The researchers aimed to estimate how many adults in the US would be considered eligible for statin therapy under the new 2026 blood cholesterol guidelines issued by the American Heart **** ociation, the American College of Cardiology and nine partnering medical societies, compared with the previous 2018 guidelines.
The **** ysis, published July 20 in the journal JAMA, found that the changes could bring the total number of Americans eligible for statins, medications that lower cholesterol, to about 87.5 million people, or more than half of adults ages 30 to 79.
What prompted this major expansion, and does being eligible mean that someone should immediately begin taking medication? To help us understand the study and what patients should discuss with their healthcare providers, I spoke with CNN wellness expert Dr. Leana Wen. Wen is an emergency physician and clinical **** ociate professor at George Washington University. She previously served as Baltimore's health commissioner.
CNN: Who are the millions of Americans who are newly eligible for statins and why?
#statins #cholesterol
3 months ago
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
A couple, 37 and 39, spent three rounds of IVF over two years before a successful pregnancy, financing each round on credit cards and a fertility specific loan when insurance covered almost none of it. The balance now sits at $52,000, and with a baby due in four months, they're trying to figure out how to pay it down before childcare costs stack on top of it.
Fertility treatment coverage varies enormously by state and employer, and only a limited number of states currently mandate any insurance coverage for IVF specifically. Most couples paying out of pocket are covering costs that can run $15,000 to $20,000 per round once medications, monitoring, and the procedure itself are included.
Don't Miss:
1.5M+ Users. $29M Raised. Shares Still at $0.79 — Learn How to Invest Before the Deadline
#coverage #benzinga #miss #users
A couple, 37 and 39, spent three rounds of IVF over two years before a successful pregnancy, financing each round on credit cards and a fertility specific loan when insurance covered almost none of it. The balance now sits at $52,000, and with a baby due in four months, they're trying to figure out how to pay it down before childcare costs stack on top of it.
Fertility treatment coverage varies enormously by state and employer, and only a limited number of states currently mandate any insurance coverage for IVF specifically. Most couples paying out of pocket are covering costs that can run $15,000 to $20,000 per round once medications, monitoring, and the procedure itself are included.
Don't Miss:
1.5M+ Users. $29M Raised. Shares Still at $0.79 — Learn How to Invest Before the Deadline
#coverage #benzinga #miss #users
3 months ago
Moon Capital Management, LLC, an investment management company, released its second quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 index rebounded in the second quarter, achieving a 9.6% return for the first half of the year, while Moon Capital Management's equity portfolio gained 4%. AI-related stocks led market performance, mitigating geopolitical concerns. Moon Capital holds 10% of its portfolio in technology, significantly less than the S&P 500's 39%. The firm remains cautious about large AI investments and their potential return on investment. In addition, please check the Strategy's top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Moon Capital Management highlighted Zoetis Inc. (NYSE:ZTS) as a newly added position. Zoetis Inc. (NYSE:ZTS) is an animal health company focused on animal health medications, vaccines, and diagnostic products. On July 22, 2026, Zoetis Inc. (NYSE:ZTS) closed at $74.19 per share. One-month return of Zoetis Inc. (NYSE:ZTS) was -4.66%, and its shares lost 51.45% over the past 52 weeks. Zoetis Inc. (NYSE:ZTS) has a market capitalization of $31.1 billion.
Moon Capital Management stated the following regarding Zoetis Inc. (NYSE:ZTS) in its Q2 2026 investor update:
"We added one new stock to the portfolio last quarter, Zoetis Inc. (NYSE:ZTS). (Our average purchase price was about $73.20/share.) Zoetis is the world's largest pure-play animal health company. We have long viewed Zoetis as one of the highest-quality businesses in healthcare (albeit for mostly four legged patients), and the company has generally been valued accordingly. However, temporary concerns around slower companion animal growth and increased competitive pressures created an opportunity to purchase the company at an attractive price. After trading above 30 times earnings for much of the past decade, Zoetis now has a P/E of less than 11x, a valuation we believe significantly understates the quality, durability, and long-term earnings power of the business.
The animal health industry is attractive as it combines the defensive characteristics of healthcare investing with a more favorable industry structure than traditional pharmaceuticals. In contrast to human healthcare, a significant portion of animal health spending is paid directly by owners, which reduces reimbursement pressure. The industry also benefits from lower research and development costs, shorter development timelines, and strong relationships with veterinarians. These relationships, combined with regulatory barriers and specialized technical expertise, create meaningful switching costs and contribute to long product lifecycles..." (Click here to read the full text)
#capital
In its Q2 2026 investor letter, Moon Capital Management highlighted Zoetis Inc. (NYSE:ZTS) as a newly added position. Zoetis Inc. (NYSE:ZTS) is an animal health company focused on animal health medications, vaccines, and diagnostic products. On July 22, 2026, Zoetis Inc. (NYSE:ZTS) closed at $74.19 per share. One-month return of Zoetis Inc. (NYSE:ZTS) was -4.66%, and its shares lost 51.45% over the past 52 weeks. Zoetis Inc. (NYSE:ZTS) has a market capitalization of $31.1 billion.
Moon Capital Management stated the following regarding Zoetis Inc. (NYSE:ZTS) in its Q2 2026 investor update:
"We added one new stock to the portfolio last quarter, Zoetis Inc. (NYSE:ZTS). (Our average purchase price was about $73.20/share.) Zoetis is the world's largest pure-play animal health company. We have long viewed Zoetis as one of the highest-quality businesses in healthcare (albeit for mostly four legged patients), and the company has generally been valued accordingly. However, temporary concerns around slower companion animal growth and increased competitive pressures created an opportunity to purchase the company at an attractive price. After trading above 30 times earnings for much of the past decade, Zoetis now has a P/E of less than 11x, a valuation we believe significantly understates the quality, durability, and long-term earnings power of the business.
The animal health industry is attractive as it combines the defensive characteristics of healthcare investing with a more favorable industry structure than traditional pharmaceuticals. In contrast to human healthcare, a significant portion of animal health spending is paid directly by owners, which reduces reimbursement pressure. The industry also benefits from lower research and development costs, shorter development timelines, and strong relationships with veterinarians. These relationships, combined with regulatory barriers and specialized technical expertise, create meaningful switching costs and contribute to long product lifecycles..." (Click here to read the full text)
#capital
3 months ago
For the first time in the program's history, Medicare is covering weight-loss drugs, and the price tag looks almost too good to pass up.
Beginning July 1, eligible Part D enrollees can access medications including Wegovy, Foundayo, and the Zepbound KwikPen for a flat $50 monthly copay through a temporary federal demonstration called the Medicare GLP-1 (glucagon-like peptide-1) Bridge.
That is a massive discount compared to the retail price of these drugs, which can exceed $1,000 per month without insurance coverage.
It arrives at a moment when roughly 56% of GLP-1 users say affordability is a significant challenge, a poll from KFF, the health policy research organization, found.
But this is not traditional Part D coverage, and the distinction creates financial consequences that could blindside enrollees who ******* ume the program works like every other Medicare prescription benefit they have used.
#part #drugs
Beginning July 1, eligible Part D enrollees can access medications including Wegovy, Foundayo, and the Zepbound KwikPen for a flat $50 monthly copay through a temporary federal demonstration called the Medicare GLP-1 (glucagon-like peptide-1) Bridge.
That is a massive discount compared to the retail price of these drugs, which can exceed $1,000 per month without insurance coverage.
It arrives at a moment when roughly 56% of GLP-1 users say affordability is a significant challenge, a poll from KFF, the health policy research organization, found.
But this is not traditional Part D coverage, and the distinction creates financial consequences that could blindside enrollees who ******* ume the program works like every other Medicare prescription benefit they have used.
#part #drugs
